Autopsy report · NCT04093648
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Cause of deathOther
“The key elements of this study were incorporated into another study.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Hepatocellular Carcinoma; Hepatoblastoma
- Interventions
- TEGAR T cells; Cytoxan; Fludarabine
- Participants
- 0
Trials that died the same way
- Use of Magnetic Imaging to Asses the Efficacy of Cap Assisted Colonoscopy in Reducing Looping and Improving Patient Acceptance for the Colonoscopy Procedure
“The study was incorporated in another study.” - Use of NAVA in Intubated Preterm
“Another institution performed the study” - Magnetic Resonance Imaging-Portfolio Diet Study #7
“Study was amalgamated with another study to include exercise as another intervention.” - Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
“study merged with another study” - Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
“The study had been revised and made a new application.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.